| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CGEM | Common Stock | Sale | -$10.1K | -347 | -0.12% | $29.05 | 281K | Aug 11, 2021 | Direct | F1, F2 |
| transaction | CGEM | Common Stock | Sale | -$72.9K | -2.51K | -0.03% | $29.05 | 7.91M | Aug 11, 2021 | See Footnote | F1, F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. |
| F4 | Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. |